Developing a New Vaccine to Fight HIV
Eliciting Broadly Neutralizing Antibody Responses against HIV-1 Fusion Peptide Epitope by AB Toxin B Subunit-Based Immunogens
This project is working to create a new type of vaccine that could help the body make strong defenses against the HIV virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11164823 on NIH RePORTER |
What this research studies
Researchers are developing a new vaccine strategy to help the immune system produce special antibodies that can neutralize many different strains of HIV. This approach focuses on a vulnerable part of the HIV virus called the fusion peptide, which is essential for the virus to infect cells. The team is using a modified component from a bacterial toxin, which has been safely used in other human vaccines, to deliver this viral piece and boost the immune response. Early tests in animals have shown promising results, leading to strong antibody responses against HIV. The goal is to create a vaccine that is both effective and safe for people.
Who could benefit from this research
Good fit: This early-stage vaccine development is not yet recruiting patients, but future studies would likely seek healthy volunteers or individuals at risk of HIV exposure.
Not a fit: Patients currently living with advanced HIV/AIDS may not directly benefit from this preventative vaccine development, though it could inform future treatments.
Why it matters
Potential benefit: If successful, this research could lead to a new and more effective vaccine to prevent HIV infection or help those living with HIV.
How similar studies have performed: Previous efforts to induce broadly neutralizing antibodies against HIV have faced challenges, but this approach builds on prior animal studies that showed promising results with a similar strategy.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Kong, Xiangpeng — New York University School of Medicine
- Study coordinator: Kong, Xiangpeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.